Loading cancer entity…
Loading cancer entity…
Clinical trials
792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00012090 | Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00021034 | Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2013 |
| clinicaltrials |
| NCT00058435 | Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00017017 | CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00003385 | Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 48 | Gynecologic Oncology GroupNETWORK | 2 | May 27, 2013 | clinicaltrials |
| NCT00003967 | Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 24 | Gynecologic Oncology GroupNETWORK | 1 | May 27, 2013 | clinicaltrials |
| NCT01851928 | Validation of a Nutrition Screening Tool | completed | — | 128 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 13, 2013 | clinicaltrials |
| NCT00003944 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Apr 17, 2013 | clinicaltrials |
| NCT00842452 | Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery | completed | Phase 1 | 26 | Steven Waggoner, MDOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00004934 | Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | completed | Phase 3 | — | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 10 | Feb 4, 2013 | clinicaltrials |
| NCT00003358 | Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00003896 | S9912 Combination Chemo in Stage III Ovarian Cancer, | completed | Phase 2 | 68 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 4, 2013 | clinicaltrials |
| NCT00672295 | PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer | completed | Phase 1 | 11 | AA SecordOTHER | 1 | Dec 28, 2012 | clinicaltrials |
| NCT00501644 | Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 59 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00059618 | PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer | completed | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00032162 | Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer | completed | Phase 1 / Phase 2 | 63 | AGO Study GroupOTHER | 1 | May 31, 2012 | clinicaltrials |
| NCT00004060 | Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | — | Daiichi SankyoINDUSTRY | 1 | May 16, 2012 | clinicaltrials |
| NCT00035100 | EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer | completed | Phase 2 | 54 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 16, 2012 | clinicaltrials |
| NCT00245050 | Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer | completed | Phase 3 | 34 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 30, 2011 | clinicaltrials |
| NCT00466986 | Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer | completed | Phase 2 | 40 | Southeastern Gynecologic OncologyOTHER | 1 | Oct 12, 2011 | clinicaltrials |
| NCT00415207 | Pharmacogenomics of Paclitaxel in Ovarian Cancer | completed | — | 300 | University of Southern DenmarkOTHER | 1 | Aug 8, 2011 | clinicaltrials |
| NCT01048814 | Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases | completed | — | 512 | Precision TherapeuticsINDUSTRY | 1 | Jun 3, 2011 | clinicaltrials |
| NCT00028912 | Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 26, 2011 | clinicaltrials |
| NCT00006391 | Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | — | NYU Langone HealthOTHER | 1 | Apr 5, 2011 | clinicaltrials |
| NCT00191646 | An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy | completed | Phase 3 | 919 | Eli Lilly and CompanyINDUSTRY | 2 | Mar 4, 2011 | clinicaltrials |
| NCT00189566 | Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse | completed | Phase 2 | 165 | ARCAGY/ GINECO GROUPOTHER | 1 | Feb 25, 2011 | clinicaltrials |
| NCT00517621 | Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire | completed | Phase 2 | 100 | ARCAGY/ GINECO GROUPOTHER | 1 | Feb 25, 2011 | clinicaltrials |
| NCT00217529 | Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00217555 | Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00063401 | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | completed | Phase 2 | 39 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 8, 2010 | clinicaltrials |
| NCT00006155 | SU5416 and Carboplatin to Treat Ovarian Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00157560 | Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma | completed | Phase 2 | 83 | Massachusetts General HospitalOTHER | 1 | Jan 3, 2008 | clinicaltrials |
| NCT00191607 | A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. | completed | Phase 3 | 162 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00074867 | Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer | completed | Phase 2 | 29 | PfizerINDUSTRY | 2 | Nov 7, 2006 | clinicaltrials |
| NCT00103545 | Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response | completed | Phase 1 / Phase 2 | 36 | AGO Study GroupOTHER | 1 | Oct 2, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Jun 18, 2013source: clinicaltrials